tofacitinibまたはTNF阻害薬で治療中の関節リウマチ患者における静脈血栓塞栓症を予測するバイオマーカー
RMD Open. 2022;8(2):e002571 doi: 10.1136/rmdopen-2022-002571
Weitz, et al. analyse 291 protein biomarkers and three genetic markers and do not identify a clear mechanistic explanation for higher rates of venous thromboembolism (VTE) with tofacitinib in the ORAL Surveillance study.